Recent research (Horgusluoglu et al., 2022) has revealed novel metabolites and potential regulatory factors in AD through integrated multi-omics data analysis, demonstrating the association between short-chain acylcarnitines/amino acids and medium−/long-chain acylcarnitines with AD clinical outcomes, and identifying the involvement of ABCA1 and CPT1A in the regulation of acylcarnitines and amino acids in AD. The gene discussed is ABCA1; the disease is Alzheimer disease.